Pharma Industry News

Following FDA’s full approval of Leqembi, here’s what else is in the Alzheimer’s pipeline

Leqembi’s U.S. approval is a milestone in Alzheimer’s research and medicine — and there are a few other late-stage biologic drugs that could follow.

Leqembi’s U.S. approval is a milestone in Alzheimer’s research and medicine — and there are a few other late-stage biologic drugs that could follow.

About the author

simom

[mwai_chat window="true" fullscreen="true"]